Skip to main content
Orphanet Journal of Rare Diseases logoLink to Orphanet Journal of Rare Diseases
. 2023 Mar 14;18:55. doi: 10.1186/s13023-023-02647-z

Correction : Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results

George A Diaz 1,, Roberto Giugliani 2, Nathalie Gufon 3, Simon A Jones 4, Eugen Mengel 5, Maurizio Scarpa 6, Peter Witters 7, Abhimanyu Yarramaneni 8, Jing Li 8, Nicole M Armstrong 9, Yong Kim 10, Catherine Ortemann-Renon 8, Monica Kumar 8
PMCID: PMC10012553  PMID: 36918897

Correction :  Orphanet Journal of Rare Diseases (2022) 17:437 https://doi.org/10.1186/s13023-022-02587-0

Following publication of the original article [1], we have been notified that Fig. 1 was published incorrectly. Correct Fig. 1 should be as per below:

Fig. 1.

Fig. 1

Patient disposition

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Diaz et al. Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results 2022;17:437. 10.1186/s13023-022-02587-0 [DOI] [PMC free article] [PubMed]

Articles from Orphanet Journal of Rare Diseases are provided here courtesy of BMC

RESOURCES